Adjuvant hepatic intra-arterial iodine-131-lipiodol following curative resection of hepatocellular carcinoma: a prospective randomized trial
| Autor: | A. Y. F. Chung, L. L. P. J. Ooi, D. Machin, S. B. Tan, B. K. P. Goh, J. S. Wong, Y. M. Chen, P. C. N. Li, M. Gandhi, C. H. Thng, S. W. K. Yu, B. S. Tan, R. H. G. Lo, A. M. M. Htoo, K. H. Tay, F. X. Sundram, A. S. W. Goh, S. P. Chew, K. H. Liau, P. K. H. Chow, Y. M. Tan, P. C. Cheow, C. K. Ho, K. C. Soo |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Male
medicine.medical_specialty Carcinoma Hepatocellular Antineoplastic Agents Gastroenterology law.invention Iodine Radioisotopes Ethiodized Oil Randomized controlled trial law Internal medicine medicine Carcinoma Humans Prospective Studies Prospective cohort study Survival rate Aged business.industry Hazard ratio Liver Neoplasms Middle Aged medicine.disease Survival Rate Treatment Outcome Injections Intra-Arterial Chemotherapy Adjuvant Hepatocellular carcinoma Lipiodol Surgery Female business Abdominal surgery medicine.drug |
| Zdroj: | World journal of surgery. 37(6) |
| ISSN: | 1432-2323 |
| Popis: | The purpose of the present study was to determine whether intrahepatic injection of (131)I-lipiodol (Lipiodol) is effective against recurrence of surgically resected hepatocellular carcinoma (HCC).From June 2001 through March 2007, this nationwide multi-center prospective randomized controlled trial enrolled 103 patients 4-6 weeks after curative resection of HCC with complete recovery (52: Lipiodol, 51: Control). Follow-up was every 3 months for 1 year, then every 6 months. Primary and secondary endpoints were recurrence-free survival (RFS) and overall survival (OS), respectively, both of which were evaluated by the Kaplan-Meier technique and summarized by the hazard ratio (HR). The design was based on information obtained from a similar trial that had been conducted in Hong Kong.The Lipiodol group showed a small, and nonsignificant, improvement over control in RFS (HR = 0.75; 95 % confidence interval [95 % CI] 0.46-1.23; p = 0.25) and OS (HR = 0.88; 95 % CI 0.51-1.51; p = 0.64). Only two serious adverse events were reported, both with hypothyroidism caused by (131)I-lipiodol and hepatic artery dissection during angiography.The randomized trial provides insufficient evidence to recommend the routine use of (131)I-lipiodol in these patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink